8
Table 4. Selected Multivariable Risk Scores to Predict
Outcome in HF
Risk Score URL/Reference
Chronic HF
All patients with chronic HF
Seattle Heart Failure Model http://SeattleHeartFailureModel.org
Heart Failure Survival Score http://handheld.sopedia.com/get/Health/
Calculator/HFSS-Calc-37354.shtml
CHARM risk score Pocock SJ, et al. Eur Heart J. 2006;27:65-75.
CORONA risk score Wedel H, et al. Eur J Heart Fail. 2009;11:281-291.
Specific to chronic HFpEF
I-PRESERVE score Komajda M, et al. Circ Heart Fail. 2011;4:27-35.
Acute Decompensated HF
ADHERE classification and
regression tree (CART) model
Fonarow GC, et al. JAMA. 2005;293:572-580.
American Heart Association
Get With e Guidelines-HF
score
http://www.heart.org/HEARTORG/
HealthcareProfessional/
GetWitheGuidelinesHFStroke/
GetWitheGuidelinesHeartFailureHomePage/
Get-With-e-Guidelines-Heart-Failure-Home- %20
Page_UCM_306087_SubHomePage.jsp
EFFECT risk score http://www.ccort.ca/Research/CHFRiskModel.aspx
ESCAPE risk model and
discharge score
O'Connor CM, et al. J Am Coll Cardiol. 2010;55:872-
878.
OPTIMIZE-HF risk-
prediction nomogram
Kociol RD, Horton JR, Fonarow GC, et al. Circ Heart
Fail. 2011;4:628-636.
Diagnostic Tests
Î Initial laboratory evaluation of patients presenting with HF should
include a complete blood cell count, urinalysis, measurement of serum
electrolytes (including calcium and magnesium), blood urea nitrogen,
serum creatinine, glucose, and thyroid-stimulating hormone, a fasting
lipid profile, and liver function tests. (I-C)
Î Serial monitoring, when indicated, should include serum electrolyte
levels and renal function. (I-C)
Î A 12-lead electrocardiogram (ECG) should be performed initially on all
patients presenting with HF. (I-C)
Î Screening for hemochromatosis or HIV is reasonable in selected
patients who present with HF. (IIa-C)
Î Diagnostic tests for rheumatological diseases, amyloidosis, or
pheochromocytoma are reasonable in patients presenting with HF in
whom there is a clinical suspicion of these diseases. (IIa-C)
Diagnosis
